• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia.新型冠状病毒肺炎恶化的早期危险因素。
J Med Virol. 2020 Nov;92(11):2593-2599. doi: 10.1002/jmv.26071. Epub 2020 Aug 21.
2
Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China.中国武汉严重肺炎患者的临床特征。
Respiration. 2020;99(8):649-657. doi: 10.1159/000507940. Epub 2020 Aug 25.
3
Predictive role of clinical features in patients with coronavirus disease 2019 for severe disease.2019冠状病毒病患者临床特征对重症疾病的预测作用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):536-541. doi: 10.11817/j.issn.1672-7347.2020.200384.
4
[Clinical characteristics and CT imaging features of patients with different clinical types of coronavirus disease 2019].2019冠状病毒病不同临床类型患者的临床特征及CT影像学特征
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):548-553. doi: 10.3760/cma.j.cn121430-20200323-00203.
5
Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus.2019新型冠状病毒感染患者队列中与疾病进展相关的危险因素。
Ann Palliat Med. 2020 Mar;9(2):428-436. doi: 10.21037/apm.2020.03.26. Epub 2020 Mar 17.
6
Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak.鉴定 COVID-19 肺炎院内死亡的风险因素——来自早期爆发的教训。
BMC Infect Dis. 2021 Jan 25;21(1):113. doi: 10.1186/s12879-021-05814-4.
7
Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China.中国湖南两中心回顾性队列研究 213 例病例:武汉以外地区 COVID-19 严重程度的临床特征和危险因素。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963035. doi: 10.1177/1753466620963035.
8
Clinical characteristics and outcomes of cancer patients with COVID-19.COVID-19 癌症患者的临床特征和结局。
J Med Virol. 2020 Oct;92(10):2067-2073. doi: 10.1002/jmv.25972. Epub 2020 Jun 2.
9
Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience.中国武汉 1663 例 COVID-19 住院患者的流行病学和临床特征:一项单中心经验。
J Infect Public Health. 2020 Sep;13(9):1202-1209. doi: 10.1016/j.jiph.2020.07.002. Epub 2020 Jul 17.
10
Clinical characteristics, laboratory abnormalities and CT findings of COVID-19 patients and risk factors of severe disease: a systematic review and meta-analysis.COVID-19 患者的临床特征、实验室异常和 CT 表现及重症危险因素的系统评价和荟萃分析。
Ann Palliat Med. 2021 Feb;10(2):1928-1949. doi: 10.21037/apm-20-1863. Epub 2021 Jan 27.

引用本文的文献

1
Construction and verification of a risk factor prediction model for neonatal severe pneumonia.新生儿重症肺炎危险因素预测模型的构建与验证
Front Med (Lausanne). 2025 Jun 2;12:1536705. doi: 10.3389/fmed.2025.1536705. eCollection 2025.
2
Risk factors and predicting nomogram for the clinical deterioration of non-severe community-acquired pneumonia.非重症社区获得性肺炎临床恶化的危险因素及预测列线图
BMC Pulm Med. 2024 Jan 27;24(1):57. doi: 10.1186/s12890-023-02813-w.
3
Effects of the pre-existing coronary heart disease on the prognosis of COVID-19 patients: A systematic review and meta-analysis.既往冠心病对 COVID-19 患者预后的影响:系统评价和荟萃分析。
PLoS One. 2023 Oct 10;18(10):e0292021. doi: 10.1371/journal.pone.0292021. eCollection 2023.
4
Performance of an AI algorithm during the different phases of the COVID pandemics: what can we learn from the AI and vice versa.人工智能算法在新冠疫情不同阶段的表现:我们能从人工智能中学到什么,反之亦然。
Eur J Radiol Open. 2023 Dec;11:100497. doi: 10.1016/j.ejro.2023.100497. Epub 2023 Jun 19.
5
Stress levels, psychological symptoms, and C-reactive protein levels in COVID-19: A cross-sectional study.新冠疫情期间的压力水平、心理症状和 C 反应蛋白水平:一项横断面研究。
J Affect Disord. 2023 Jun 1;330:216-226. doi: 10.1016/j.jad.2023.03.019. Epub 2023 Mar 11.
6
Possible Beneficial Effects of Fresh Pomegranate Juice in SARS-CoV-2 Infection Conditions.新鲜石榴汁在新冠病毒感染情况下可能产生的有益作用。
J Nutr Metab. 2022 Mar 5;2022:5134560. doi: 10.1155/2022/5134560. eCollection 2022.
7
An interpretable machine learning model based on a quick pre-screening system enables accurate deterioration risk prediction for COVID-19.基于快速预筛选系统的可解释机器学习模型可准确预测 COVID-19 恶化风险。
Sci Rep. 2021 Nov 30;11(1):23127. doi: 10.1038/s41598-021-02370-4.
8
Pannexin-1 channel opening is critical for COVID-19 pathogenesis.泛连接蛋白-1通道开放对新冠病毒发病机制至关重要。
iScience. 2021 Dec 17;24(12):103478. doi: 10.1016/j.isci.2021.103478. Epub 2021 Nov 19.
9
Biomarkers of Post-COVID Depression.新冠后抑郁症的生物标志物。
J Clin Med. 2021 Sep 14;10(18):4142. doi: 10.3390/jcm10184142.
10
Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.心脏生物标志物、心脏损伤以及与 2019 年冠状病毒病(COVID-19)严重疾病和死亡率相关的合并症:系统评价和荟萃分析。
Immun Inflamm Dis. 2021 Dec;9(4):1071-1100. doi: 10.1002/iid3.471. Epub 2021 Aug 18.

本文引用的文献

1
Convalescent plasma as a potential therapy for COVID-19.康复期血浆作为治疗新冠肺炎的一种潜在疗法。
Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.
2
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
3
Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China.突发公共卫生事件预备医疗物资供应体系面临的挑战:对中国严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫情爆发的反思。
Biosci Trends. 2020 Mar 16;14(1):3-8. doi: 10.5582/bst.2020.01043. Epub 2020 Feb 17.
4
Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.2020 年 1 月,30 个欧盟/欧洲经济区国家的专家实验室对新型冠状病毒(2019-nCoV)的实验室准备和应对情况。
Euro Surveill. 2020 Feb;25(6). doi: 10.2807/1560-7917.ES.2020.25.6.2000082. Epub 2020 Feb 11.
5
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
6
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
7
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.比较瑞德西韦与洛匹那韦利托那韦和干扰素β联合治疗中东呼吸综合征冠状病毒的疗效。
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
8
A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).中东呼吸综合征冠状病毒(MERS-CoV)治疗药物的系统评价。
Travel Med Infect Dis. 2019 Jul-Aug;30:9-18. doi: 10.1016/j.tmaid.2019.06.012. Epub 2019 Jun 25.
9
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.冠状病毒对抗病毒药物瑞德西韦(GS-5734)的易感性是由病毒聚合酶和校对核糖核酸外切酶介导的。
mBio. 2018 Mar 6;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
10
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.广谱抗病毒药物GS-5734可抑制流行性冠状病毒和人畜共患冠状病毒。
Sci Transl Med. 2017 Jun 28;9(396). doi: 10.1126/scitranslmed.aal3653.

新型冠状病毒肺炎恶化的早期危险因素。

Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia.

机构信息

Department of Gastroenterology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China.

Department of General Surgery, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei, China.

出版信息

J Med Virol. 2020 Nov;92(11):2593-2599. doi: 10.1002/jmv.26071. Epub 2020 Aug 21.

DOI:10.1002/jmv.26071
PMID:32470167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7283729/
Abstract

The purpose of this study was to investigate the early risk factors for the exacerbation of coronavirus disease 2019 (COVID-19) pneumonia. Restrospective analysis of clinical data of 85 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including gender, age, comorbidities, symptoms, blood routine, clotting profile, biochemical examination, albumin, myocardial enzyme profile, inflammatory markers, and chest computed tomography (CT). All laboratory examinations were measured within first 24 hours after admission, and chest CT was performed before admission. A total of 56 (65.9%) patients had a history of exposure to the Huanan seafood market in Wuhan. Fever and dry cough accounted for the highest percentage of all symptoms. Male COVID-2019 patients were more likely to develop severe pneumonia. Patients with severe and critical conditions are older and have higher rates of hypertension (P = .003) and coronary heart disease (P = .017). All severe and critical patients infected with SARS-CoV-2 showed bilateral lung involvement and have more multiple lobes involvement than common patients (P < .001). Severe and critical patients showed higher white blood cell count (P = .006), neutrophil (NEU) count (P = .001), NEU% (P = .002), procalcitonin (P = .011), C-reactive protein (P = .003), prothrombin time (P = .035), D-dimer (P = .025), aspartate aminotransferase (P = .006), and lower lymphocyte (LYM) count (P = .019), LYM% (P = .001), albumin (P < .001). Logistic regression analysis showed that NEU count is an independent risk factor for deterioration, with the threshold of 6.5 × 10 ·L . We concluded that the laboratory independent risk factor for the progression of COVID-19 pneumonia is NEU count. In addition, COVID-19 patients with bilateral lung involvement or multiple lobes involvement should be taken seriously and actively treated to prevent deterioration of the disease.

摘要

本研究旨在探讨 2019 年冠状病毒病(COVID-19)肺炎恶化的早期危险因素。回顾性分析 85 例严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染患者的临床资料,包括性别、年龄、合并症、症状、血常规、凝血谱、生化检查、白蛋白、心肌酶谱、炎症标志物和胸部计算机断层扫描(CT)。所有实验室检查均在入院后 24 小时内测量,入院前进行胸部 CT 检查。共有 56 例(65.9%)患者有武汉华南海鲜市场暴露史。发热和干咳占所有症状的比例最高。男性 COVID-2019 患者更易发生重症肺炎。重症和危重症患者年龄较大,高血压(P=.003)和冠心病(P=.017)的发生率较高。所有感染 SARS-CoV-2 的重症和危重症患者均表现为双肺受累,且多发病灶受累多于普通患者(P<.001)。重症和危重症患者的白细胞计数(P=.006)、中性粒细胞(NEU)计数(P=.001)、NEU%(P=.002)、降钙素原(P=.011)、C 反应蛋白(P=.003)、凝血酶原时间(P=.035)、D-二聚体(P=.025)、天冬氨酸转氨酶(P=.006)较高,淋巴细胞(LYM)计数(P=.019)、LYM%(P=.001)、白蛋白(P<.001)较低。Logistic 回归分析显示,NEU 计数是病情恶化的独立危险因素,其阈值为 6.5×10·L-1。我们得出结论,COVID-19 肺炎进展的实验室独立危险因素是 NEU 计数。此外,应重视 COVID-19 患者双肺受累或多发病灶受累,并积极治疗,防止病情恶化。